Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Ca... (ing time totumor progression duration of...)

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial

Date:4/29/2008

ing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive bavituximab alone after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable.

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with cancer of the breast in 2007 and about 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase Ib pilot trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has received regulatory approval to conduct three Phase II trials to study the anti-tumor effects of bavituximab in combination with chemotherapy. These include two breast cancer protocols and a non-small cell lung cancer protocol. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV

Post Your Comments:

(Date:5/21/2013)... -- Tom Daulton, CEO of Mammotome, a division of Devicor Medical ... Cincinnati chapter of the Association for ... top executive who is also a breast cancer survivor, led ... March of 2010. Daulton will be presented with the award ... Bank, on May 22. The ACG Deal Maker ...

(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...

(Date:5/21/2013)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include Actavis, Inc.,s (NYSE: ACT ), BP plc ... ), Petrobras (NYSE: PBR ) and Devon Energy ... http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get the most recent ...

Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2 Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2 Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3 The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2 The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3 The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4 The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5

[0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia [0] The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy

... , NATICK, Mass. and BARCELONA, Spain, ... BSX ) today announced two-year data from its SYNTAX ... TAXUS((R)) Express((R)) Paclitaxel-Eluting Coronary Stent System to coronary artery ... no statistically significant difference between PCI and CABG in ...

... , Timing is what matters in treating ... Ill., Sept. 1 Trauma patients who sustain multiple fractures ... emergency department. A review article published in the September 2009 issue ... (JAAOS) explains that trauma patients who have several orthopaedic injuries ...

Cached Medicine Technology:Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery 2 Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery 3 Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery 4 Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery 5 Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases 2 Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases 3

Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases

(Date:5/21/2013)... St. Petersburg, FL (PRWEB) May 22, 2013 ... Sale" of Cellulite Whisperer ® products has begun with ... it is tied to estrogen. Many women get the dreaded ... fatty deposits just beneath the skin where they have been ... appearance. While there are no easy fixes, a specific program ...

(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are meant to ... on the latest weight loss methods by publishing weekly in-depth ... review of Kyle Leon’s Customized Fat Loss Plan ... lose weight or stay in shape with the minimum effort. ... by a popular fitness trainer, Kyle Leon, who has made ...

(Date:5/21/2013)... Primary care practice transformation on a large ... reform efforts aimed at achieving better outcomes, better ... evidence that transformation toward the patient-centered medical home ... care environment, the U.S. Department of Health and ... funded 14 studies to learn more about the ...

(Date:5/21/2013)... Texas (PRWEB) May 21, 2013 HealthSmart ... Its expanding national presence has required the hiring of ... , HealthSmart is pleased to announce that Dawn Powell ... is serving as the Director of Account Management in ... Corporate offices in Irving, Texas. With extensive client management, ...

(Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...

Breaking Medicine News(10 mins):Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2 Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:New Talent Joins the HealthSmart Account Management Team 2 Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2

[0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"[0] Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] New Talent Joins the HealthSmart Account Management Team [0] Botox – Is the World’s Most Popular Cosmetic Procedure Safe?

... ... quarter of fiscal 2009, a 26% ... Strong sales to pharmaceutical manufacturers and retail market customers ... quarter - Strong operating leverage drives bottom-line expansion, ...

... Support New Ambulatory Musculoskeletal Center, NEW YORK, ... New York,s,philanthropic, business, government, medical and civic communities ... Steven A. Stuchin,and long-serving board member and philanthropist ... (NYUHJD) 2008 Founders Gala. This event at the,Waldorf=Astoria ...

... Kris Clark, Ph.D., offers easy tips ... fun - Halloween!, WASHINGTON, Oct. 27 If this ... five to thirteen years, are,poised to don costumes to go ... sweet treats, registered dietitian Kris Clark,Ph.D., of Pennsylvania State University, ...

... Care Knowledge Releases Study on the Value of ... Consumer-Directed Health ... released by,the WellPoint Institute of Health Care Knowledge (Institute) today,researchers ... second study released by the Institute, entitled,"Employers and Consumers Recognize ...

... has received the first annual Vision Award for Business Impact for ... speed of demographic and clinical healthcare data. , ... ... processing healthcare data, think fast. , , , , ,LifeMasters ...

... Statins, the class of drugs commonly used for lowering ... thrombosis (DVT) or blood clots, an affliction that occurs ... presented at CHEST 2008, the 74th annual international scientific ... suggests that the use of statins may be associated ...

Cached Medicine News:Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 2 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 3 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 4 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 5 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 6 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 7 Health News:Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 8 Health News:Norma Smith and Dr. Steven A. Stuchin honored at 2008 Founders Gala for NYU Hospital for Joint Diseases 2 Health News:No Trick to Halloween Sweet Treats 2 Health News:No Trick to Halloween Sweet Treats 3 Health News:Research Shows Consumer-Directed Health Plans Encourage Preventive Care 2 Health News:Research Shows Consumer-Directed Health Plans Encourage Preventive Care 3 Health News:LifeMasters Receives 2008 Vision Award for Business Impact 2 Health News:LifeMasters Receives 2008 Vision Award for Business Impact 3 Health News:Statins show promise for blood clot prevention 2

Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009 Norma Smith and Dr. Steven A. Stuchin honored at 2008 Founders Gala for NYU Hospital for Joint Diseases No Trick to Halloween Sweet Treats Research Shows Consumer-Directed Health Plans Encourage Preventive Care LifeMasters Receives 2008 Vision Award for Business Impact Statins show promise for blood clot prevention

... is a microprocessor-controlled programmable power supply ... current and high current/low voltage applications ... is ideal for sample fractionation, IPG ... The low voltage/high current section is ...

... modified battery chargers are ... for GENIE blotters. They ... very specific voltages, giving ... laboratory power supplies. 110 ...

Inquire...

... Elchrom Scientific PSE Power Supply . ... provides 200 V and 2 A in 1 ... possible to run up to three SEA 2000® ... of programmed preset and actual values of voltage, ...

Medicine Products:

ZOOM® Dual Power (100-120 VAC 47 - 60 Hz)GENIE POWER SUPPLIES (6 and 12 volt, 10 amp output, with timer)EPS 3501 XL Power Supply PSE Electrophoresis Power Supply